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Background: Peroxisome proliferator activated receptor-γ (PPAR-γ) is a ligand-dependent transcription factor that
plays important roles in cellular proliferation and differentiation. It has been implicated as a tumor suppressor in
many solid tumors including human prostate, breast, colon, and lung cancer. The objective of this study was to
determine the tissue distribution of PPAR-γ in normal canine lung, canine lung cancer, and metastatic to lung
cancer, as well as determine the role, if any, of DNA methylation in epigenetic control of gene expression. The
protein was studied using immunohistochemistry (IHC) and DNA methylation was studied using combined bisulfite
restriction analysis (COBRA), and methylation-specific PCR (MSP).
Results: PPAR-γ is expressed in all large conducting airways, particularly in goblet cells and bronchial glands, in the
canine lung. The protein is also expressed in interstitial macrophages. PPAR-γ is expressed in 33 % of canine non-
small cell lung cancer (NSCLC) cases and 66 % of metastatic osteosarcoma (OSA) cases. There is a significant loss of
5′ PPAR-γ methylation from normal lung to primary lung cancer and metastatic OSA (p = 0.0002), however altered
PPAR-γ promoter methylation at the interrogated locus does not appear to be associated with changes in protein
expression.
Conclusions: PPAR-γ protein is expressed in normal canine lung tissue, canine primary lung cancer, and metastatic
OSA. Confirmation of PPAR-γ protein expression in tumor-bearing dogs supports the investigation of PPAR-γ
agonists in this subset of veterinary patients. These results are the first to describe epigenetic marks and protein
localization of PPAR-γ among different lung pathologies in the dog.
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Peroxisome proliferator activated receptor-γ (PPAR-γ) is
one of three members (α, β, γ) of the PPAR nuclear hor-
mone receptor superfamily of ligand-dependent transcrip-
tion factors. Natural ligands for PPAR-γ include fatty acids
and eicosanoids [1]. PPAR-γ expression is prominent in
adipocytes and its function is best described in regulating
lipid metabolism, but PPAR-γ plays a more general role in
cellular proliferation, differentiation, and survival, as well
as acting as a negative regulator of inflammation [2, 3].
More recently, it has also been implicated as a tumor sup-
pressor gene [4], and appears dysregulated in many hu-
man cancers including those of prostate, breast, colon,
and lung. Research is rapidly discovering carcinogenic
processes in which PPAR-γ is altered at the epigenetic,
genetic and protein levels [5].
One of the most active areas of research is examining
the role of PPAR-γ in lung cancer. Both human and
murine studies have demonstrated that up-regulation of
PPAR-γ can slow lung tumor development via reduced
proliferation, decreased production of inflammatory cy-
tokines, and promotion of a more differentiated pheno-
type [6–8]. Currently, lung cancer is the most common
human cancer in the world and the leading cause of can-
cer related death [9]. Primary lung cancer (PLC) is di-
vided into small-cell lung cancer (SCLC) and non-small
cell lung cancer (NSCLC) with NSCLC predominating.
Despite many advances in human oncologic surgery and
chemotherapy, the 5 year survival rate for NSCLC re-
mains lower than 15 % [9]. Due to these dismal survival
rates, new approaches to cancer therapy are being inves-
tigated, including modulation of PPAR-γ. In fact, several
studies have shown that artificial activation of PPAR-γ
can inhibit growth of lung cancer cells, primarily through
differentiation and apoptosis [10, 11].
The dog has proven repeatedly to be an excellent trans-
lational model for many human cancers. The dog shares
many similarities with humans in respect to genetic ab-
errations leading to cancer, development of naturally
occurring histologically similar cancers, environmental
exposures, and similar responses to treatments includ-
ing radiation, chemotherapy, and monoclonal antibody
immunotherapy [12, 13]. Although rare in the dog, the
species does serve as a good translational model for
NSCLC in that dogs naturally develop NSCLC, are ex-
posed to similar environmental inhalants, have a similar
respiratory system anatomy, and similar size and distri-
bution of primary lung tumors [14]. In addition, some
genetic aberrations that occur in human NSCLC have
also been documented in the dog including k-ras muta-
tions and altered expression of proteins associated with
chemotherapy resistance [15, 16]. And finally, the dog
has also been used to demonstrate efficacy of new lung
cancer therapies in humans, including use of inhalantchemotherapy [17, 18]. There is limited research describ-
ing PPAR-γ expression in the dog in health or disease. In-
formation is specifically lacking in the contribution of this
gene to carcinogenesis. Alterations in PPAR-γ expression
have, however, been implicated in canine testicular tumors
and nasal carcinomas [19, 20].
There are no reports of PPAR-γ expression in the canine
lung or canine lung cancer. PPAR-γ agonists in the thiazo-
lidinedione class (predominantly rosiglitazone) have been
studied preliminarily in the dog, including pharmacokinet-
ics and metabolism of this drug [21, 22]. More intriguing
is that recent research suggests that the combination of
PPAR-γ agonists with platinum based chemotherapy are
synergistic in treating NSCLC in vitro for human NSCLC
and in vivo in murine models. Additionally, safety of oral
rosiglitazone and carboplatin was recently published in a
phase I clinical trial for cancer-bearing dogs [23]. Given
this information, dogs may serve as an excellent model of
naturally occurring NSCLC to study the efficacy and toler-
ability of combination PPARγ agonists and platinum-
based drugs for treatment of lung cancer. The protein
may also be important in metastatic cancers like osteosar-
coma, but this has not been evaluated in the dog.
Given that dogs develop NSCLC and are a good
in vivo model for studying the effects of PPAR-γ ago-
nists, it is critical to understand the expression of this
protein and possible epigenetic control in the normal ca-
nine lung and canine lung cancer. The objective of this
investigation was to identify PPAR-γ expression at the
protein and epigenetic level in NSCLC and normal lung.
In addition, as some protein alterations are necessary for
carcinogenesis, and some are cancer specific, we also
evaluated metastatic to lung osteosarcoma, to serve as
an aggressive model of metastatic to lung cancer and a
cancer control. The protein was studied in these groups
through immunohistochemistry (IHC) and promoter
methylation was studied using combined bisulfite re-
striction analysis (COBRA), and methylation-specific
PCR (MSP). The hypotheses were that PPAR-γ would
act as a tumor suppressor, and therefore have decreased
expression with increasing malignancy, and that this would
correspond with more complete 5′ PPAR-γ methylation.
Results
Patient demographics
The median ages of dogs were as follows: 8.3 years for
the control group, 11.8 years for the NSCLC group, and
8.4 years for the OSA group. The NSCLC group was sta-
tistically older than both the OSA and control groups
(p: 0.002 and 0.001 respectively). There was no statis-
tical difference in gender between any of the groups
(p = 0.658) (Table 1).
Prior to evaluation, all cases (except P-13) were reviewed
by DYK to confirm the necropsy report diagnosis. All cases
Table 1 Signalment and immunohistochemistry summary for all subjects evaluated
Dog Age (years) Sex Breed Conducting Airwayb Macrophagesb Tumorb H&E Histologic Diagnosis
C-1 14 MC Border Collie n/a (−) n/a Normal Lung
C-2 4 MC Australian Shepherd n/a (−) n/a Normal Lung
C-3 7 MC Mixed n/a (−) n/a Normal Lung
C-4 5 FS Mixed (+) (−) n/a Normal Lung
C-5 8 MC Dachshund (+) (−) n/a Normal Lung
C-6 8 MC German Shepherd n/a (−) n/a Normal Lung
C-7 5 FS Dachshund n/a (−) n/a Normal Lung
C-9 7 FS Mixed n/a (−) n/a Normal Lung
C-10 7 MC Doberman Pinscher n/a (−) n/a Normal Lung
C-15 13 MI Mixed (+) (−) n/a Normal Lung
C-17 9 FS Labrador Retriever (+) (−) n/a Normal Lung
C-18 7 FS Shih Tzu n/a (−) n/a Normal Lung
C-19 9 MC Boxer n/a (−) n/a Normal Lung
C-20 10 FI Labrador Retriever n/a (−) n/a Normal Lung
C-21 12 MC West Highland Terrier (+) (−) n/a Normal Lung
C-22 9 MC Mixed n/a (−) n/a Normal Lung
O-2 10 MC Weimaraner (+) (−) (−) Metastatic Osteosarcoma
O-3 8 MI Rottweiler (+) (+) (−) Metastatic Osteosarcoma
O-4 7 MC Golden Retriever n/a (+) (+) Metastatic Osteosarcoma
O-5 10 FS Mixed n/a (−) (+) Metastatic Osteosarcoma
O-6 5 MC Labrador Retriever a a a Metastatic Osteosarcoma
O-9 10 FS Staffordshire Terrier (+) (−) (+) Metastatic Osteosarcoma
O-10 8 MC Great Dane n/a (−) (+) Metastatic Osteosarcoma
O-11 5 MC Golden Retriever (+) (−) (+) Metastatic Osteosarcoma
O-12 10 FS Mixed (+) (+) (−) Metastatic Osteosarcoma
O-13 11 FS Mixed (+) (−) (+) Metastatic Osteosarcoma
P-1 11 MC Mixed (+) (−) (−) Large cell carcinoma
P-3 14 FS Bichon Frise (+) (+) (+) Bronchioloalveolar carcinoma
P-4 11 FS Greyhound (−) (+) (−) Adenosquamous carcinoma
P-8 9 FS Scottish Terrier (+) (−) (−) Bronchioloalveolar carcinoma
P-9 13 MC Mixed (+) (+) (−) Bronchioloalveolar carcinoma
P-10 10 MC Cocker Spaniel (+) (−) (−) Bronchioloalveolar carcinoma
P-12 10 FS Boston Terrier (+) (−) (+) Bronchial gland carcinoma
P-13 10 MC Boxer a a a Acinar Pulmonary adenocarcinomaa
P-14 12 FS Gordon Setter (+) (+) (−) Papillary adenocarcinoma
P-15 14 MC Mixed (+) (−) (+) Papillary adenocarcinoma
P-16 14 FS Welsh Corgi (+) (−) (−) Large cell carcinoma
P-17 15 MC Welsh Corgi (+) (+) (+) Solid adenocarcinoma
P-19 11 FS Mixed (+) (−) (−) Bronchioloalveolar carcinoma
MC male castrated; MI male intact; FS female spayed; FI female intact; (-) Negative/None/Few/Low; (+) Positive/Mild/Moderate/High/Intense; n/a not
evaluable/not present
anot included in IHC analysis, italics = this diagnosis was made by necropsy pathologist, unable to confirm specific subtype, bSee materials and methods
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firmed as such by pathologist review (16 cases). The same
was true of all metastatic OSA (10 cases). The NSCLC
cases that could be reviewed (12 cases) were further classi-
fied as pulmonary adenocarcinoma: papillary type (2 cases)
and solid type (1 cases); bronchioloalveolar carcinoma
(5 cases); bronchial gland carcinoma (1 case); adenos-
quamous carcinoma (1 case); and large-cell carcinoma
(2 cases) (Table 1).COBRA
There was a significant difference in methylated band
maximum intensities between groups (p = 0.0002). Nor-
mal lung tissue had the most complete methylation at
the evaluated CG site, with primary lung cancer showing
relative loss of methylation, and metastatic to lung
osteosarcoma being least methylated (Fig. 1).
Bisulfite converted normal canine spleen and Sssi
treated and bisulfite converted normal canine spleen
were both positive for methylation at this site, suggesting
that methylation is expected to be present, even in nor-
mal tissues.Methylation specific PCR
All but one sample of primary lung cancer (case ID C-7)
and all samples of osteosarcoma were amplified by MSP
using primers for methylated CG. Normal lung tissue
samples also amplified with the methylated MSP primers
(Fig. 2).
The same spleen tissue was used to investigate other
genes using MSP primers in an unrelated study includingFig. 1 Box Plot of Methylation Intensity of Osteosarcoma, Primary
Lung Cancer, and Normal Control Lung. The box incorporates the
middle quartiles; the line represents the median value: the whiskers
indicate the minimum and maximum values. There is loss of
methylation in primary lung cancer (Primary Lung) as compared to
normal control lung (Control Lung). There is further loss of methylation
in osteosarcoma (OSA). The difference is significant (p = 0.0002)HOXA9, DLX13, DLX15, HOXB5, and CDA and was not
methylated in any case (data not shown).
Western blot
PPAR-γ protein expression of the appropriate molecular
weight of 57 kDa was identified via Western blot in both
fresh canine lung and fresh canine placenta (Fig. 3). Hu-
man PC3 cells were used as a positive control.
Immunohistochemistry
Immunohistochemistry performed on canine placenta
(positive control) revealed nuclear staining of tropho-
blast cells as expected for normal PPAR-γ localization
(Fig. 4).
The majority of bronchi and large bronchioles had
strong PPAR-γ positive cytoplasmic immunoreactivity in
the epithelium, particularly of goblet cells, and bronchial
glands, though not every sample had a large conducting
airway present on the slide. In some cases, only tumor
tissue was present on the slide, while in others, both
tumor and normal tissue were present. Thirty one per-
cent (31 %) of control cases, 66 % of OSA, and 100 % of
NSCLC had a large airway available for evaluation, and
in every case this airway was positive (Table 1 and
Fig. 5a).
Most of the peribronchiolar interstitial macrophages
that were markedly swollen with carbon particles were
strongly positive. If these macrophages were absent or
rare, the cases were scored as 0. The cases containing
moderate to high numbers of these macrophages were
scored as 1 (Fig. 5b), which occurred in 0 % of control
cases, 33 % of OSA, and 42 % of NSCLC. Tumor tissue
was immunopositive for PPAR-γ in 66 % of OSA cases
and 33 % of NSCLC cases. The tumor tissue was par-
tially stained. The positive stains were observed multifo-
cally within the OSA but often at the periphery in the
NSCLC (Table 1 and Fig. 5c-d).
There was no association between methylation of the
gene in primary lung cancer cases and expression of
the protein in the tumor tissue (p = .497), large airways
(p = 0.931), or macrophages (p = 0.931). There was no
association between methylation of the gene in meta-
static to lung osteosarcoma cases and expression of the
protein in the tumor tissue (p = .429), large airways
(p = 1.0), or macrophages (p = 0.571).
Discussion
In general, it is believed that in carcinogenesis there is a
shift in the epigenetic profile of cells in which genome
wide hypomethylation develops, accompanied by regional
hypermethylation, specifically in promoter regions of genes.
When hypermethylation occurs in promoter regions of
tumor suppressor genes, transcription machinery often is
impaired, and therefore gene transcription is inhibited. As
Fig. 2 COBRA and MSP for Osteosarcoma, Primary Lung Cancer, and Normal Control Lung. PCR products were run on a 1.5 % agarose gel. Lad = 100 bp
ladder. Samples labeled O-X are osteosarcoma, P-X are primary lung cancer, and C-X are control lung. X represents the patient number. Sssi is normal
canine spleen DNA methylated in vitro and Spl is normal canine spleen DNA. Sample C-7 did not amplify by MSP
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cancer development, we hypothesized that PPAR-γ pro-
moter would be hypermethylated in all tumor samples, and
that frequency of hypermethylation would be greater
in the more biologically aggressive cancer (metastaticFig. 3 PPARγ Western Blot. Western blot analysis for the expression
of PPARγ in fresh tissue samples of human PC3 cells (positive for
PPARγ) (1), normal canine placenta (2) and two samples of normal
canine lung samples (3 and 4) show protein expression of appropriate
weight (57 kDa). The predicted canine protein is 38 amino acids longer
than the human protein, which is reflected in the decreased migration
of the band on the Western blot (human NM_005037.5 and canine
NM_001024632.2). Samples were concurrently formalin fixed and
stained with H&E to confirm that they were histologically normalOSA) than in primary lung tumors. Our findings are
the opposite, in that methylation of PPAR-γ was re-
duced in primary lung cancer as compared to normal
lung, and even further loss of methylation occurred in
aggressive metastatic to lung osteosarcoma. The inter-
rogated region was selected based on prior data gener-
ated in our laboratory identifying methylation at this
locus in canine lymphoma. The methylation previously
was identified in spite of a lack of a formal CpG island
in the region. It does not appear that the interrogatedFig. 4 Immunohistochemistry of PPARγ in canine placenta. This 400X
view of the canine placenta clearly shows nuclear staining of the
trophoblast cells by the antibody
Fig. 5 Immunohistochemistry of PPARγ in canine lung tissue. The respiratory epithelium of bronchi and large bronchioles exhibited immunoreactivity
of PPARγ, most strongly in the goblet cells (a) and engorged peribronchiolar interstitial macrophages that were often filled with carbon particles (b).
Some of the primary pulmonary adenocarcinomas (c) and metastatic osteosarcomas (d) expressed positive immunoreactivity. Bar = 100 μm
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evaluated tissues (Fig. 6). These CG dinucleotides may
then act as genomic CGs, as opposed to promoter
CGs, and therefore have little impact on gene expres-
sion. If acting as genomic CGs, loss of methylation
with increasing malignancy would be expected, as was
identified here. It is also possible that the queried CGs
were too far from the transcription start site to modify
gene expression [24]. It is also possible, but less likely,
that PPAR-γ is serving as a tumor promoter, instead of
a tumor suppressor, and that methylation decreases
with increasing malignancy, although these data did
not demonstrate such a relationship. It is unclear as to
why C-7 would not amplify by MSP, though this was
the case with multiple attempts at the experiment. In
spite of measurable DNA in the sample, it is mostFig. 6 Schematic representation PPARγ gene. The location of the promoter, aslikely that the sample was partially degraded, making it
difficult to amplify with MSP primers, or that the amp-
lification is below the visible limit of detection.
Bisulfite treatment of DNA results in conversion of
cytosine to uracil, but leaves 5-methylcytosine unaltered.
Sssi treatment converts all cytosines to 5-methylcytosine.
In these samples, both bisulfite converted normal ca-
nine spleen and Sssi treated and bisulfite converted nor-
mal canine spleen were positive for methylation. The
most logical explanation for this finding is native hyper-
methylation at the investigated locus. The methylation
status of PPAR-γ in normal canine spleen has not been
reported previously, and to the authors’ knowledge has
not been investigated in normal human spleen. PPAR-γ
protein expression is reported to be high in the rat
spleen however [3, 25]. In unpublished data evaluatingwell as the sites of interrogation by MSP and COBRA primers is represented
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genes, DNA from spleen tissue of the same dog did not
show hypermethylation. The repeatable nature of the
finding at this locus, along with negative tumor tissues,
supports its validity.
The immunohistochemistry results of this study are the
first to describe PPAR-γ protein localization in normal ca-
nine lung and canine lung cancer. Studies of PPAR-γ ex-
pression in other species are similar to the findings here.
Cytoplasmic PPAR-γ expression was found in the epithe-
lium of large conducting airways [26] and in alveolar mac-
rophages [27, 28]. PPAR-γ expression has also been
described in alveolar epithelial cells in some studies, but
was not identified here [27, 28]. Reasons for differences
across species could be due to true differences in PPAR-γ
expression within the lung, due to differences in tissue
processing and therefore antibody binding, or due to dif-
ferences in sensitivity of detection.
This is the first study to describe immunohistochemi-
cal positivity for either metastatic or primary lung tu-
mors in the dog. The incidence of IHC positive cases of
NSCLC in dogs (33 %) is similar to studies in human
NSCLC, which found that 42–45 % of cases were posi-
tive [29, 30]. As in human NSCLC [29, 30], the cytoplas-
mic distribution was also found here. It is unclear why
PPAR-γ is primarily cytoplasmic in both human and canine
NSCLC, however various other carcinomas have described
primarily cytoplasmic PPAR-γ staining [31, 32]. One pro-
posed mechanism by which PPAR-γ is trapped in the cyto-
plasm is nitration, which inhibits translocation into the
nucleus. This has been demonstrated in a macrophage-like
cell line, although further investigation would be necessary
to determine if this is the mechanism at play here [33]. In
some human NSCLC studies, it has been found that ex-
pression of PPAR-γ correlated with tumor type and grade
[29], while in other studies no such correlation existed
[30]. Due to the small number of samples in this study, no
attempt was made to correlate histologic subtype or tumor
grade to PPAR-γ positivity. This would be a next reason-
able step for future studies where larger patient numbers
could be obtained.
To the authors’ knowledge, IHC evaluation of PPAR-γ
in primary or metastatic OSA has not been described in
any species. Studies of human OSA cell lines have
shown increased PPAR-γ mRNA message, suggesting
that this tumor does express PPAR-γ [34]. It is also
known that PPAR-γ is important for osteoblast differen-
tiation [35, 36], and there is some suggestion that PPAR-
γ agonists could inhibit OSA proliferation and induce
apoptosis [37]. From the present findings, it is impos-
sible to speculate on the role that PPAR-γ may play in
OSA tumorigenesis, but it does provide the first investi-
gation of PPAR-γ expression in metastatic OSA in the
dog. In addition, it would be interesting to compare theprimary tumor from OSA samples to the corresponding
metastatic pulmonary lesions, however this was not pos-
sible with the cases available, as the primary tumors
were often removed prior to necropsy, making tissues
unavailable for comparison.
There are some limitations to the materials in the
present study. An attempt was made during case selec-
tion to age-match controls to the tumor groups through
exclusion of cases < 5 years of age. This arbitrary age
was selected to remove very young dogs from the con-
trol group, as methylation of tissues has been shown to
increase with age [38]. This method allowed for age-
matching between the OSA group and the control
group, however the NSCLC group was significantly
older. These age differences are, however, consistent
with age at diagnosis in other reports, in which the aver-
age age at diagnosis of primary lung tumors is 11 years
whereas the average age at OSA diagnosis is 7–9 years
[39, 40]. It is very uncommon for animals in the patient
database at or around 11 years of age to be submitted
for elective necropsy and have histologically normal lung
tissue on necropsy and no other tumor capable of me-
tastasis. This explains why an older group of control ani-
mals was not identified. Additionally, the tumor type
distribution for primary lung tumors is also consistent
with what has previously been reported, with adenocar-
cinoma and bronchoalveolar carcinoma being the most
common primary lung tumors of dogs [41, 42].
There was some sample loss in comparing cases that
had adequate tissue for IHC as compared to cases that
had adequate tissue for COBRA and MSP. The reason
for the loss of available tissue for epigenetic studies is a
direct reflection of the type/size of samples used for this
study. All tissues in this study were obtained from ar-
chived patient tissues. All samples were obtained from a
veterinary diagnostic laboratory, and as such were con-
sidered a part of the patient medical record, therefore,
the majority of the tissue had to be preserved to main-
tain the integrity of the medical record. For all IHC sam-
ples, only a single 5 um slice needed to be harvested
from the archived block, and did not result in deterior-
ation of the patient sample, so could be performed for
most cases identified. For DNA harvest, a maximum of
40um slice of tissue could be trimmed from the tissue
before interfering with preservation of the patient med-
ical record. In cases of normal control lung, often only
small pieces of lung tissue were included in the paraffin
embedded block, and were also often combined with up
to five other tissues from the same patient. In these
cases, only lung tissue was processed. If adequate DNA
could not be harvested after a single extraction, the
blocks could not be disrupted further. For tumor cases,
often the entire paraffin embedded block consisted of
the pathologic sample, so there was a high percentage of
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formed due to the large amount of preserved tissue. This
is the same reason that not all tissue had a large airway
available for evaluation of PPAR-γ expression via immu-
nohistochemistry. In general, with the smaller samples
available for normal control lung, it is not surprising that
many sections did not have large airways present for
evaluation. In future studies, using tissue collected spe-
cifically for the designed study could result in a higher
percentage of cases that have adequate DNA available
for methylation analysis as well as ensure that all types
of lung tissue (conducting airways and alveoli) would be
available for evaluation by immunohistochemistry.
The most important finding of this study is the dem-
onstration of lung tumor positivity for PPAR-γ in dogs
with NSCLC and metastatic OSA. There are currently
no published successful medical treatments for either of
these conditions in the dog. Dogs with high tumor stage
or lymph node metastasis with primary lung tumors have
median survival times of < 2 months [43]. Dogs with
metastatic OSA have a median survival of < 2-3 months,
even with treatment [44]. PPAR-γ agonists including rosi-
glitazone and pioglitazone have been studied in the dog,
and therapeutic doses and dose-limiting toxicities are pub-
lished [45, 46]. In addition, a phase I clinical trial of oral
rosiglitazone and carboplatin in cancer-bearing dogs
showed that this combination was safe [23]. The findings
of this study provide rationale to suggest that dogs with
primary lung tumor and metastatic osteosarcoma could
serve as a population which would be appropriate to treat
with PPAR-γ agonists, and that expression of PPAR-γ can
be demonstrated in these tumor types.
Conclusions
The results of this study show that PPAR-γ protein is
expressed in normal canine lung tissue and in canine
primary and metastatic to lung cancer. This report is the
first to demonstrate that the frequency of PPAR-γ pro-
tein expression in canine primary lung cancer is similar
to the frequency described in human NSCLC. These
data supports the use of PPAR-γ agonists in this subset
of veterinary patients, and suggest that the dog may
serve as an appropriate translational model for the study
of PPAR-γ agonist use in lung cancer treatment. There
are differences in PPAR-γ methylation among normal
lung, primary lung cancer, and metastatic osteosarcoma




The University of Missouri Veterinary Diagnostic La-
boratory (VMDL) UVIS database was queried from 2005
to 2011 to identify tissue samples for analysis. Becauseno tissue was collected from a live animal or human for
purposes of the study, and all were de-identified of client
and patient information beyond age, sex, and breed, no
ethical approvals were required for the study. All nec-
ropsy submissions to the VMDL include permission for
use of collected tissues in future research.
For selection of tumor-bearing cases, the database was
searched for dogs with a diagnosis of OSA, metastatic
OSA, pulmonary carcinoma, pulmonary adenocarcinoma
or bronchiolar carcinoma. Cases were included if a sample
or biopsy of the affected lung tissue was obtained and sub-
mitted for diagnosis and archiving. The hematoxylin and
eosin-stained (H&E) slides from these cases were reviewed
by a single pathologist (DYK) to confirm that lung tissue
was present and support the original diagnosis of either
metastatic OSA or NSCLC. DNA was extracted from
paraffin-embedded lung tissue blocks using a commer-
cially available DNA extraction kit (NucleoSpin Tissue,
Machery-Nagel. Düren, Germany).
For normal lung control animals, the database was
searched for any animals for which a necropsy was per-
formed and non-diseased lung tissue was reported in the
necropsy report and for which formalin fixed and embed-
ded paraffin blocks were archived. Cases were excluded if
a metastatic or primary lung tumor was identified, if the
dog had cancer elsewhere that could reasonably be ex-
pected to metastasize, or if significant lung disease was re-
ported. Cases were also excluded if significant liver or
kidney disease was noted in the medical record to prevent
detection of changes in the methylation status of DNA
due to systemic disease. Significant liver and kidney dis-
ease was defined as a diagnosis code entry in the patient
record to include inflammatory/infectious conditions (any
hepatitis or nephritis), any neoplasia in these organs, or
any diagnosis code of significant organ dysfunction or fail-
ure (liver failure, hepatopathy, renal failure, nephropathy).
In addition, if these diagnoses were noted in the necropsy
report, but not entered as a diagnostic code, the cases
were also excluded. Finally, cases with an age < 5 years
were excluded in an attempt to age match the control
cases, and exclude methylation changes with age as a con-
founder. The slides and tissues were then collected,
reviewed, and processed as described above.
For both immunohistochemistry and methylation ana-
lysis, when more than one tissue type was present in the
archived tissue block, only the lung tissue was collected
for analysis by trimming away all non-lung derived tis-
sue. Thirteen cases of metastatic to lung OSA (cases
O-1 thru 13), 19 cases of NSCLC (cases P-1 thru 19),
and 22 control cases were identified (cases C-1 thru 22).
From these cases identified for inclusion in the study, 10
cases of OSA, 12 cases of NSCLC, and 16 cases of nor-
mal lung had tissue available for pathologist review of
the H&E stained slides (Table 1 column 8). From the
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12 cases of NSCLC, and 16 control lung had adequate
samples available for immunohistochemistry. Also from
the identified cases, 9 cases of OSA (case O-2 unavail-
able), 12 cases of NSCLC, and 8 cases (C-1, 6, 7, 15, 17,
18, 19, 21) of control lungs had enough DNA to perform
COBRA/MSP.
DNA extraction and methylation analysis
DNA was harvested using NucleoSpin Tissue (Machery-
Nagel. Düren, Germany) according to the provided pro-
tocols. Briefly, xylene and ethanol was used to remove
paraffin-wax from the embedded tissue samples. The
cells were lysed and proteins digested with Proteinase K,
and ethanol was added to adjust DNA binding condi-
tions. The solution was then centrifuged in a spin col-
umn provided with the kit to bind the total DNA. The
DNA was washed twice and finally eluted as a highly
pure product.
COBRA: The MethPrimer (http://www.urogene.org/
cgi-bin/methprimer/methprimer.cgi) website was used
to identify an appropriate primer using as input the ca-
nine gene located at the 5′ end of the PPAR-γ (RefSeq
NM_001024632.2) chr20:6,210,096-6,210,218 CanFam2
[47]. The product size of these primers is 124 bp and
contains one TaqaI cut site yielding fragments of 86 and
38 bp. The primers used for COBRA were (5′ to 3′): for-
ward, TTTTTAGAAGTGTTTGAATTATTGGG and re-
verse, AAAAACAAACTCCATACAAAAAACC. PCR
was performed at an annealing temperature of 60 °C for
60 s, an extension temperature of 72 °C for 60 s, and a
melting temperature of 95 °C for 60 s, repeating for
36 cycles. The PCR product was purified with the
NucleoSpin Gel and PCR Clean-up kit (Macherey-Nagel,
Bethlehem, PA) and eluted in 20 μL of HyPure water.
For TaqaI digestion, 10 μL of PCR product was added to
2.5 μL of Buffer 2, 1 μL of TaqaI, and 11.5 μL of HyPure
water, and incubated at 60 °C for 4 h. A schematic repre-
sentation of the PPAR-γ gene is shown in Fig. 6.
MSP was performed on the lung tissue samples de-
scribed above using PPAR-γ primers created in the re-
gion 5′ from the promoter from MethPrimer (http://
www.urogene.org/cgi-bin/methprimer/methprimer.cgi).
Primers were against bisulfite-treated DNA located at
chr20:6,206,804-6,210,823. This region was identified in
other, unrelated experiments to be hypermethylated in
canine cancers (data not shown). The forward and reverse
sequences were AATTGATTTATATTGATAGGTTGGC
and TTCCATACTAAAATTTAACACGAC respectively.
Using bisulfite treated canine DNA from normal spleen,
the conditions for MSP were optimized. The methylated
primer was used to amplify the region with an annealing
temperature appropriate to the primer design for 30 s, an
extension temperature of 72 °C for 30 s, and a meltingtemperature of 95 °C for 15 s, repeating for 32 cycles. The
PCR products were run on a 1.5 % agarose gel with Gel
Red. The controls for COBRA and MSP consisted of bi-
sulfite converted DNA from normal canine spleen, and
DNA from a normal canine spleen methylated in vitro
using SssI, then bisulfite converted (to induce methylation
of the sample).
Methylation intensity of the COBRA assay was deter-
mined using Image J. Regions of interest were created
around the region of the primary band (123 bp) and
each cut band (85 bp and 39 bp). A ratio was calculated
with the added intensities of the cut bands (methylated)
over the intensity of the primary band (unmethylated).
The higher the ratio, the greater the relative proportion
of methylation in the sample.
Immunohistochemistry
From the archived tissues of adequate condition, 9 cases
of OSA, 12 cases of NSCLC, and 16 control lung sam-
ples were processed for PPAR-γ immunohistochemistry
evaluation and scoring. For immunohistochemistry, the
paraffin blocks of the selected cases were sectioned by
5 μm. Anti-human PPAR-gamma rabbit polyclonal anti-
body (sc-7196, Santa Cruz Biotechnology, Dallas, TX)
served as the primary antibody. Heat-induced antigen
retrieval using citrate buffer (0.01 M, pH 6.0) and EnVi-
sion™+ system (Dako, Carpinteria, CA) were used. The
immunoreactivity was visualized by using Romulin AEC
Chromogen (Biocare Medical, Concord, CA) and haema-
toxylin was used as counterstain. In each case, negative
controls were included in which the primary antibody was
excluded. For a positive control, fresh canine placenta was
used, as this has been previously demonstrated as positive
in the dog [48].
Western blot
Western blot analysis was performed on fresh canine
lung and fresh canine placenta confirmed by H&E as
microscopically non-diseased tissue as well as human
PC3 cells. The fresh canine lung was obtained from a
dog that had been euthanized for unrelated causes and
submitted to VMDL for necropsy. The fresh canine pla-
centa was obtained from a local breeder and client of
the University of Missouri VMTH who volunteered the
tissues immediately after whelping. The human PC3
cells were obtained from the American Type Culture
Collection (www.atcc.org). No special permissions or
ethical approval was required for use of the fresh canine
and human tissue. Tissue lysate was treated with M-PER
mammalian protein extraction reagent (Thermo-Fisher,
Rockford, IL) as per manufacturer’s instruction. Protein
concentration was determined using the Bradford
method (Thermo-Fisher,Rockford, IL). Equal amounts of
protein (~ 40 μg) were separated on a 10 % SDS
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membrane (Bio-Rad, Hercules, CA). The blots were
blocked at room temperature for 1 h using Tris-saline buf-
fer (TBS) containing 0.1 % Tween 20 and 10 % nonfat
milk. The membrane was further incubated with primary
antibody for PPAR-γ (sc-7196, Santa Cruz Biotechnology)
overnight at 4 °C. After washing with TBS, the membrane
was incubated with a horseradish peroxidase-labeled sec-
ondary antibody and visualized with a chemiluminescence
detection kit (Thermo-Fisher, Rockford, IL). The blot was
imaged using a Kodak imaging station (Carestream Health,
Rochester, NY).
Evaluation of immunohistochemistry
The slides were reviewed and scored by a pathologist
(DYK). Some epithelial cells and goblet cells of bronchi
and large bronchioles, some bronchial glands, peribronch-
iolar interstitial macrophages that often were filled with
carbon particles, and tumor cells were positive for PPAR-γ
IHC expression. Each structure/cell type above was scored
separately. The absence of positive staining in bronchi/
bronchioles was scored 0 (−) and presence was scored
1 (+). For the peribronchiolar interstitial macrophages,
0 (−) represented zero to few positive macrophages and
1 (+) represented moderate to high numbers of immu-
nopositive macrophages. For tumor cells 0 (−) repre-
sented no positivity and 1 (+) represented mild to
intense immunopositivity.
Statistical analysis
Age and gender comparisons were made using an ANOVA
on Ranks. Methylation intensities were compared in cat-
egorical variables using a Mann-Whitney U test. Associ-
ation between gene methylation and tissue expression were
made using an ANOVA on Ranks. P-values less than or
equal to 0.05 were considered significant.
Availability of supporting data
All necessary data is included in the body of this
manuscript.
Abbreviations
COBRA: Combined bisulfite restriction analysis; IHC: Immunohistochemistry;
MSP: Methylation specific PCR; NSCLC: Non-small cell lung cancer;
OSA: Osteosarcoma; PPARγ: Peroxisome proliferator activated receptor;
SCLC: Small cell lung cancer.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CH carried out case selection and DNA extraction and drafted the
manuscript. JNB and CH carried out MSP and COBRA. DYK performed all
immunohistochemical evaluation and helped draft this portion of the
manuscript. SK participated in the design of the study and aided in
laboratory technique. JNB helped conceive the study, participated in its
design and coordination, performed the statistical analysis, and helped to
draft the manuscript. All authors read and approved the final manuscript.Acknowledgements
The authors would like to thank Dr. Kim Selting for helpful discussion and
identification of cases used in this study. This work was previously presented
at the 32nd Annual Conference of the Veterinary Cancer Society, Las Vegas,
NV, October 18–21, 2012 and partially funded by a Phi Zeta grant from the
University of Missouri.
Author details
1Veterinary Medicine and Surgery, College of Veterinary Medicine, University
of Missouri, Columbia MO 65211, USA. 2Veterinary Medical Diagnostic
Laboratory, College of Veterinary Medicine, University of Missouri, Columbia
MO 65211, USA. 3Current Address: BluePearl Seattle, 11536 Lake City Way NE,
Seattle WA 98125, USA.
Received: 30 April 2015 Accepted: 21 August 2015
References
1. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, et al.
Fatty acids and eicosanoids regulate gene expression through direct
interactions with peroxisome proliferator-activated receptors α and γ. Proc
Natl Acad Sci. 1997;94:4318–23.
2. Chinetti G, Fruchart J-C, Staels B. Peroxisome proliferator-activated receptors
(PPARs): Nuclear receptors at the crossroads between lipid metabolism and
inflammation. Inflamm Res. 2000;49:497–505.
3. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-
activated receptor-γ is a negative regulator of macrophage activation.
Nature. 1998;391:79–82.
4. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome
proliferator-activated receptor gamma agonists. Lancet Oncol. 2004;5:419–29.
5. Peters JM, Shah YM, Gonzalez FJ. The role of peroxisome proliferator-
activated receptors in carcinogenesis and chemoprevention. Nat Rev
Cancer. 2012;12:181–95.
6. Han SW, Roman J. Activated PPARgamma targets surface and intracellular
signals that inhibit the proliferation of lung carcinoma cells. PPAR Res.
2008;2008:254108.
7. Keshamouni VG, Reddy RC, Arenberg DA, Joel B, Thannickal VJ, Kalemkerian
GP, et al. Peroxisome proliferator-activated receptor-γ activation inhibits
tumor progression in non-small-cell lung cancer. Oncogene. 2004;23:100–8.
8. Li H, Weiser-Evans MCM, Nemenoff R. Anti- and protumorigenic effects of
PPARγ; in lung cancer progression: a double-edged sword. PPAR Res.
2012;2012.
9. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin.
2010;60:277–300.
10. Chang T-H, Szabo E. Induction of differentiation and apoptosis by ligands of
peroxisome proliferator-activated receptor γ in non-small cell lung cancer.
Cancer Res. 2000;60:1129–38.
11. Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, et al.
Inhibition of human lung cancer cell growth by the peroxisome
proliferator-activated receptor-γ agonists through induction of apoptosis.
Biochem Biophys Res Commun. 2000;270:400–5.
12. Rowell JL, McCarthy DO, Alvarez CE. Dog models of naturally occurring
cancer. Trends Mol Med. 2011;17:380–8.
13. Breen M, Modiano JF. Evolutionarily conserved cytogenetic changes in
hematological malignancies of dogs and humans – man and his best friend
share more than companionship. Chromosome Res. 2008;16:145–54.
14. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs
to humans. Nat Rev Cancer. 2008;8:147–56.
15. Kraegel SA, Gumerlock PH, Dungworth DL, Oreffo VIC, Madewell BR. K-ras
activation in Non-small cell lung cancer in the dog. Cancer Res. 1992;52:4724–7.
16. Hifumi T, Miyoshi N, Kawaguchi H, Nomura K, Yasuda N.
Immunohistochemical detection of proteins associated with multidrug
resistance to anti-cancer drugs in canine and feline primary pulmonary
carcinoma. J Vet Med Sci Jpn Soc Vet Sci. 2010;72:665–8.
17. Khanna C, Vail DM. Targeting the lung: preclinical and comparative
evaluation of anticancer aerosols in dogs with naturally occurring cancers.
Curr Cancer Drug Targets. 2003;3:265–73.
18. Hershey IDK AE. Inhalation chemotherapy for macroscopic primary or
metastatic lung tumors: proof of principle using dogs with spontaneously
occurring tumors as a model. Clin Cancer Res Off J Am Assoc Cancer Res.
1999;5:2653–9.
Herrera et al. BMC Veterinary Research  (2015) 11:230 Page 11 of 1119. Sozmen M, Kabak YB, Gulbahar MY, Gacar A, Karayigit MO, Guvenc T, et al.
Immunohistochemical characterization of peroxisome proliferator-activated
receptors in canine normal testis and testicular tumours. J Comp Pathol.
2013;149:10–8.
20. Paciello O, Borzacchiello G, Varricchio E, Papparella S. Expression of
peroxisome proliferator-activated receptor gamma (PPAR-γ) in canine nasal
carcinomas. J Vet Med Ser A. 2007;54:406–10.
21. Toseland CDN, Campbell S, Francis I, Bugelski PJ, Mehdi N. Comparison of
adipose tissue changes following administration of rosiglitazone in the dog
and rat. Diabetes Obes Metab. 2001;3:163–70.
22. Frazier SA, McKemie DS, Guerrero TA, Skorupski KA, Rodriguez CO.
Evaluation of an extractionless high-performance liquid chromatography-
tandem mass spectrometry method for detection and quantitation of
rosiglitazone in canine plasma. Am J Vet Res. 2011;72:263–70.
23. Allstadt Frazier S, McKemie DS, Guerrero TA, LaChapelle H, Skorupski KA, Kass
PH, et al. Phase I clinical trial of oral rosiglitazone in combination with
intravenous carboplatin in cancer-bearing dogs. Vet Comp Oncol. 2014;12:1–9.
24. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies
and beyond. Nat Rev Genet. 2012;13:484–92.
25. Braissant O, Foufelle F, Scotto C, Dauça M, Wahli W. Differential expression of
peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-
alpha, -beta, and -gamma in the adult rat. Endocrinology. 1996;137:354–66.
26. Simon DM, Arikan MC, Srisuma S, Bhattacharya S, Tsai LW, Ingenito EP, et al.
Epithelial cell PPARγ contributes to normal lung maturation. FASEB J.
2006;20:1507–9.
27. Liu D, Xiong Zeng B, Shang Y. Decreased expression of peroxisome
proliferator-activated receptor γ in endotoxin-induced acute lung injury.
Physiol Res. 2006;55:291–9.
28. Ameshima S, Golpon H, Cool CD, Chan D, Vandivier RW, Gardai SJ, et al.
Peroxisome proliferator-activated receptor gamma (PPARγ) expression is
decreased in pulmonary hypertension and affects endothelial cell growth.
Circ Res. 2003;92:1162–9.
29. Theocharis S, Kanelli H, Politi E, Margeli A, Karkandaris C, Philippides T, et al.
Expression of peroxisome proliferator activated receptor-gamma in non-
small cell lung carcinoma: correlation with histological type and grade.
Lung Cancer. 2002;36:249–55.
30. Giaginis C, Politi E, Alexandrou P, Sfiniadakis J, Kouraklis G, Theocharis S.
Expression of peroxisome proliferator activated receptor-gamma (PPAR-γ) in
human non-small cell lung carcinoma: correlation with clinicopathological
parameters, proliferation and apoptosis related molecules and patients’
survival. Pathol Oncol Res. 2012;18:875–83.
31. Mukunyadzi P, Ai L, Portilla D, Barnes EL, Fan C-Y. Expression of peroxisome
proliferator-activated receptor gamma in salivary duct carcinoma:
immunohistochemical analysis of 15 cases. Mod Pathol. 2003;16:1218–23.
32. Zhang GY, Ahmed N, Riley C, Oliva K, Barker G, Quinn MA, et al. Enhanced
expression of peroxisome proliferator-activated receptor gamma in
epithelial ovarian carcinoma. Br J Cancer. 2004;92:113–9.
33. Shibuya A, Wada K, Nakajima A, Saeki M, Katayama K, Mayumi T, et al.
Nitration of PPARgamma inhibits ligand-dependent translocation into the
nucleus in a macrophage-like cell line, RAW 264. FEBS Lett. 2002;525:43–7.
34. Haydon RC, Zhou L, Feng T, Breyer B, Cheng H, Jiang W, et al. Nuclear
receptor agonists as potential differentiation therapy agents for human
osteosarcoma. Clin Cancer Res. 2002;8:1288–94.
35. Haydon RC, Luu HH, He T-C. Osteosarcoma and osteoblastic differentiation:
a new perspective on oncogenesis. Clin Orthop. 2007;454:237–46.
36. Tang N, Song W-X, Luo J, Haydon RC, He T-C. Osteosarcoma development
and stem cell differentiation. Clin Orthop. 2008;466:2114–30.
37. Wagner ER, He B-C, Chen L, Zuo G-W, Zhang W, Shi Q, et al. Therapeutic
Implications of PPARγ in Human Osteosarcoma. PPAR Res 2010, 2010.
doi: 10.1155/2010/956427
38. Fuke C, Shimabukuro M, Petronis A, Sugimoto J, Oda T, Miura K, et al. Age
related changes in 5-methylcytosine content in human peripheral leukocytes
and placentas: an HPLC-based study. Ann Hum Genet. 2004;68:196–204.
39. Ru G, Terracini B, Glickman LT. Host related risk factors for canine
osteosarcoma. Vet J. 1998;156:31–9.
40. Withrow SJ, Vail DM, Page RL. Withrow and MacEwen’s small animal clinical
oncology. London: Elsevier Health Sciences; 2013.
41. Griffey SM, Kraegel SA, Madewell BR. Rapid detection of K-ras gene
mutations in canine lung cancer using single-strand conformational
polymorphism analysis. Carcinogenesis. 1998;19:959–63.42. Ogilvie GK, Haschek WM, Withrow SJ, Richardson RC, Harvey HJ, Henderson RA,
et al. Classification of primary lung tumors in dogs: 210 cases (1975–1985). J
Am Vet Med Assoc. 1989;195:106–8.
43. Polton GA, Brearley MJ, Powell SM, Burton CA. Impact of primary tumour
stage on survival in dogs with solitary lung tumours. J Small Anim Pract.
2008;49:66–71.
44. Boston SE, Ehrhart NP, Dernell WS, Lafferty M, Withrow SJ. Evaluation of
survival time in dogs with stage III osteosarcoma that undergo treatment:
90 cases (1985–2004). J Am Vet Med Assoc. 2006;228:1905–8.
45. Boileau C, Martel-Pelletier J, Fahmi H, Mineau F, Boily M, Pelletier J-P. The
peroxisome proliferator–activated receptor γ agonist pioglitazone reduces
the development of cartilage lesions in an experimental dog model of
osteoarthritis: In vivo protective effects mediated through the inhibition of
key signaling and catabolic pathways. Arthritis Rheum. 2007;56:2288–98.
46. Nemoto S, Razeghi P, Ishiyama M, Freitas GD, Taegtmeyer H, Carabello BA.
PPAR-γ agonist rosiglitazone ameliorates ventricular dysfunction in
experimental chronic mitral regurgitation. Am J Physiol - Heart Circ Physiol.
2005;288:H77–82.
47. Li L-C, Dahiya R. MethPrimer: designing primers for methylation PCRs.
Bioinforma Oxf Engl. 2002;18:1427–31.
48. Kowalewski MP, Meyer A, Hoffmann B, Aslan S, Boos A. Expression and
functional implications of Peroxisome Proliferator—Activated Receptor
Gamma (PPARγ) in canine reproductive tissues during normal pregnancy
and parturition and at antiprogestin induced abortion. Theriogenology.
2011;75:877–86.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
